Back to Search
Start Over
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
- Source :
- Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
- Publication Year :
- 2021
- Publisher :
- Nature Portfolio, 2021.
-
Abstract
- Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung cancer to cause resistance.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 12
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.57a69b4d14e444839652b6a01ced7b32
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-021-21396-w